Monogram Orthopaedics Inc (MGRM) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 695.98K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.16
• Revenue Growth: -100.00%
• EPS Growth: -43.67%
• Country: US
• Employees: 27
• Sector: Healthcare
• Sector Strength: 53
• Industry: Medical - Devices
• EPS (TTM): -0.16
• Shares Outstanding: 40,632,366
• 10 Day Avg. Volume: 154,832
• 30 Day Avg. Volume: 695,978
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: 211.75
• Enterprise Value/Gross Profit: -590.30
• Enterprise Value/Ebitda: -6.37
• 1Y Price Target: $10.80
• Price Target Upside: 97.80% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 54 Neutral
• Price Target: ―

Monogram Orthopaedics Inc. shows promise due to significant technological advancements and recent regulatory clearances, which are key drivers for potential growth. However, financial instability, regulatory uncertainties, and ongoing profitability challenges weigh heavily on the overall score. The stock's upward momentum is a positive indicator, but valuation metrics remain weak due to negative earnings and lack of dividends.

Monogram Orthopaedics Inc Business Overview & Revenue Model

Company Description

Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable mass personalized optimization of orthopedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was incorporated in 2016 and is headquartered in Austin, Texas.

How the Company Makes Money

Monogram Orthopaedics Inc generates revenue primarily through the sale of its orthopedic implants and associated surgical systems. The company's revenue model is based on direct sales to healthcare providers, hospitals, and surgical centers. Additionally, Monogram may engage in partnerships with other medical device companies to expand its market reach and enhance its product offerings. Revenue can also be derived from licensing its proprietary technology to other entities in the medical field. The company's earnings are influenced by its ability to innovate and bring cutting-edge solutions to market, as well as its capacity to establish relationships with key stakeholders in the healthcare industry.

Monogram Orthopaedics Inc Financial Statement Overview

Summary

Monogram Orthopaedics Inc. faces significant financial challenges, primarily due to its inability to generate revenue and achieve profitability. While the balance sheet shows manageable debt levels, the company's cash flow constraints highlight operational inefficiencies. To improve its financial standing, the company needs to focus on revenue generation and operational optimization, reducing its dependence on external financing.

Income Statement

Monogram Orthopaedics Inc. has consistently struggled with generating revenue, with $0 revenue reported in 2024. Despite a brief increase in 2021, the revenue trend remains negative. Gross profit margins remain non-existent, and the company continues to operate at a loss, as evidenced by negative EBIT and net income. These factors highlight significant challenges in scaling operations and achieving profitability.

Balance Sheet

The company maintains a reasonable debt-to-equity ratio, thanks to low levels of debt and a positive equity base. However, the equity ratio indicates limited asset backing. While liabilities are relatively small, the company must improve its equity position to strengthen financial stability. The balance sheet suggests a need for strategic asset growth to enhance financial health.

Cash Flow

Operating cash flow has been persistently negative, indicating cash flow challenges in daily operations. Although financing activities have bolstered cash reserves, the lack of free cash flow growth poses concerns. The reliance on financing for cash flow sustainability is a potential risk factor, emphasizing the need for improved operational efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	425.49K	0.00	365.00K	0.00	628.25K	0.00
Gross Profit	-152.63K	-430.00K	365.00K	-386.69K	169.57K	-95.69K
EBITDA	-14.15M	-15.90M	-16.86M	-10.23M	-9.96M	-6.76M
Net Income	-17.91M	-16.33M	-13.75M	-13.69M	-11.81M	-9.07M
Balance Sheet
Total Assets	15.00M	17.77M	16.58M	13.69M	8.72M	8.12M
Cash, Cash Equivalents and Short-Term Investments	12.83M	15.66M	13.59M	10.47M	5.54M	5.59M
Total Debt	296.00K	364.00K	491.99K	610.15K	211.46K	205.49K
Total Liabilities	6.38M	3.27M	3.18M	9.54M	5.21M	3.13M
Stockholders Equity	8.62M	14.50M	13.40M	4.15M	3.50M	4.99M
Cash Flow
Free Cash Flow	-7.56M	-14.05M	-13.61M	-8.66M	-10.17M	-6.74M
Operating Cash Flow	-7.49M	-13.97M	-13.54M	-8.42M	-9.17M	-5.40M
Investing Cash Flow	-446.61K	-84.00K	-64.91K	-241.20K	-1.01M	-1.33M
Financing Cash Flow	18.08M	16.12M	16.73M	13.59M	10.12M	10.01M

Monogram Orthopaedics Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.46
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGRM, the sentiment is Positive. The current price of 5.46 is above the 20-day moving average (MA) of 5.45, above the 50-day MA of 4.45, and above the 200-day MA of 3.03, indicating a bullish trend. The MACD of 0.20 indicates Positive momentum. The RSI at 65.67 is Neutral, neither overbought nor oversold. The STOCH value of 54.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MGRM.

Monogram Orthopaedics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	¥352.94B	11.56	-1.45%	2.37%	9.60%	-12.34%
XTNT	58 Neutral	$80.80M	―	-9.80%	―	15.16%	-39.18%
MGRM	54 Neutral		―	-228.80%	―	-100.00%	-43.67%
OFIX	54 Neutral	$572.67M	―	-24.63%	―	4.84%	0.85%
KIDS	50 Neutral	$479.66M	―	-11.49%	―	26.08%	-63.67%
BBLG	―	$4.04M	―	-88.80%	―	―	―
TNON	53 Neutral	$12.43M	―	-335.48%	―	-12.60%	95.87%

Monogram Orthopaedics Inc Corporate Events

Monogram Orthopaedics Gains Approval for Indian Clinical Trials

On April 29, 2025, Monogram Technologies Inc. announced it received regulatory approval from India’s Central Drugs Standard Control Organization to conduct clinical trials for its mBôs TKA system. This approval marks a significant milestone for Monogram, as it collaborates with Shalby Hospitals to evaluate the safety and effectiveness of its system in a 102-patient trial. The initiative is expected to enhance Monogram’s industry positioning by demonstrating the system’s performance in real surgical settings, potentially advancing orthopedic innovation globally.

Spark’s Take on MGRM Stock

According to Spark, TipRanks’ AI Analyst, MGRM is a Neutral.

Monogram Orthopaedics Inc. has strengths in recent FDA approval and technological advancements, which are key positive drivers. However, financial instability, regulatory uncertainties, and negative profitability weigh heavily on the overall score. While technical indicators show upward momentum, the high RSI indicates potential risk of a pullback. Valuation metrics are weak due to the lack of profitability and dividends.

To see Spark’s full report on MGRM stock, click here.

Monogram Orthopaedics Gains FDA Clearance for TKA System

On March 17, 2025, Monogram Technologies Inc. announced that it received FDA 510(k) clearance for its Monogram mBôs™ TKA System, allowing it to market the device under specific regulatory provisions. This clearance marks a significant milestone for the company, highlighting years of innovation and teamwork in advancing orthopedic robotics. The system is designed to enhance safety, efficiency, and accuracy in robotic-assisted total knee arthroplasty and is positioned for future expansion into other orthopedic applications. The company is preparing for commercialization and aims to establish clinical experience with key surgeons to demonstrate the system’s advantages. This development opens new domestic and international opportunities, supporting Monogram’s strategic growth and long-term commercialization strategy.

Monogram Orthopaedics Awaits FDA Clearance for mBôs TKA System

On February 25, 2025, Monogram Technologies Inc. announced the completion of supplemental testing and submission of a formal response to the FDA’s Additional Information Request for its mBôs TKA System. The company anticipates a favorable clearance decision, which would allow commercialization in the U.S. Monogram also held an Investigator Meeting in India as part of a collaboration with Shalby Limited and Reliance Life Sciences to prepare for a clinical trial of the mBôs TKA System. The company has made significant advancements in its robotic system, enhancing cutting speeds and maintaining accuracy, positioning it as a competitive solution in the orthopedic robotics market.